Digestive disorder (medical condition): Any condition that involves the digestive tract. The conditions may range from benign to serious. Some examples include duodenal ulcer, esophageal achalasia, fecal incontinence, Whipple disease and dysentery.
A study called “Cannabinoid Hyperemesis [severe nausea/vomiting] Syndrome: Clinical Diagnosis of an Underrecognised Manifestation of Chronic Cannabis Abuse” at Creighton University Medical Center in Omaha, Nebraska, states:
“Cannabis is a common drug of abuse that is associated with various long-term and short-term adverse effects. The nature of its association with vomiting after chronic abuse is obscure and is under recognized by clinicians. In some patients this vomiting can take on a pattern similar to cyclic vomiting syndrome with a peculiar compulsive hot bathing pattern, which relieves intense feelings of nausea and accompanying symptoms. In this case report, we describe a twenty-two year-old-male with a history of chronic cannabis abuse presenting with recurrent vomiting, intense nausea and abdominal pain. In addition, the patient reported that the hot baths improved his symptoms during these episodes. Abstinence from cannabis led to resolution of the vomiting symptoms and abdominal pain. We conclude that in the setting of chronic cannabis abuse, patients presenting with chronic severe nausea and vomiting that can sometimes be accompanied by abdominal pain and compulsive hot bathing behaviour, in the absence of other obvious causes, a diagnosis of cannabinoid hyperemesis syndrome should be considered.”
Another study, “Cannabinoid Receptors as Novel Therapeutic Targets for the Management of Non-Alcoholic Steatohepatitis” found: “Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucial mediator of acute and chronic liver injury. Recent experimental and clinical data indicate that peripheral activation of cannabinoid CB1 receptors promotes insulin resistance and liver steatogenesis, two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors enhance progression of liver fibrogenesis. These findings provide a strong rationale for the use of CB1 antagonists in the management of NASH.”
In the case of Hepatitis C, chemotherapy-induced nausea and vomiting, as well as AIDS wasting syndrome, were improved with oral cannabinoid-containing (OC) medications. This was studied at the University of Ottawa.